Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (23599)	7/27/1998 9:27:00 PM
From: Henry Niman	Respond to of 32384

Bob, LGND has pretty much held onto oncology and dermatology applications. They are developing Panretin and Targretin for these indications. I think that they do give AGN a 6% royalty, but of course if AGN develops their compounds for these indications I believe that LGND gets 6% from AGN. The LLY deal is largely based on rexinoid applications for metabolic diseases, so they have Targretin, LGD1268 and LGD1324 applications for metabolic diseases and they also have a research program the looks at combinations of rexinoids (like LGD1268 or LGD1324) with SERMs for treating cancer (almost certainly breast cancer). LGND has held onto rights for many major diseases. the best example is SERMs, SPRMs, and SARMs. SERMs (Droloxifene, CP-366,156, TSE424, Evista) are being developed by partners (PFE, AHP, LLY). SPRMs are being developed by AHP and LGND. SARMs are held exclusively by LGND. All three of these activators of sex hormone receptors have similar properties and structures. What is learned in one system has applications for the others. LGND claims to have the largest androgen program (including SARMs) in the world, and at this time, none has been partnered out. I expect LGND to develop many of these indications independently. I also expect revenues to be applied to a wide range of developing programs, including STATs (in large part the mimics not picked up by SBH).